In vitro thymidine kinase/ganciclovir-based suicide gene therapy using replication defective herpes simplex virus-1 against leukemic B-cell malignancies (MCL, HCL, B-CLL)

Leukemia Research

Volumn 27, Issue 8, 2003, Pages 695-699

  Misumi, Motohiro ^a   Suzuki, Toshiya ^b   Moriuchi, Shusuke ^c   Glorioso, Joseph C ^d   Bessho, Masami ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b Japanese Red Cross Society   (Japan)

^c OSAKA NATIONAL HOSPITAL   (Japan)

^d UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

B cell chronic lymphocytic leukemia (B CLL); Ganciclovir (GCV); Hairy cell leukemia (HCL); Herpes simplex virus thymidine kinase (HSV TK); Leukemic B cell malignancies; Mantle cell lymphoma (MCL); Replication defective HSV 1 vector; Suicide gene therapy

Indexed keywords

GANCICLOVIR; THYMIDINE KINASE; VIRUS VECTOR;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL CHRONIC LYMPHOCYTIC LEUKEMIA; B CELL LEUKEMIA; BLOOD; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EVALUATION; EXPERIMENTAL INFECTION; FEMALE; HAIRY CELL LEUKEMIA; HERPES SIMPLEX VIRUS 1; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; MALE; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; SUICIDE GENE THERAPY; VIRUS INFECTION; VIRUS REPLICATION;

EID: 0038204243     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(02)00327-2     Document Type: Article

References (32)

1. Jaffe ES, Harris NL, Stein H, Vardiman JW, editors, Tumors of hematopoietic and lymphoid tissues. World Health Organization classification of tumors. Lyon: IARC Press; 2001.
2. Stull R.A., Szoka F.C.J. Antigene, ribozyme, and aptamer nucleic acid drugs: progress and prospects. Pharm. Res. 12:1995;465.
3. Walther W, Stein U, editors. Gene therapy of cancer. Clifton: Humana Press; 2000.
4. Goins W.F., Krisky D.M., Wolfe D.P., Fink D.J., Glorioso J.C. Development of replication-defective herpes simplex virus vectors. Methods Mol. Med. 69:2002;481.
5. Suzuki T., Piche A., Kasono K., Xiang J., Gomez-Navarro J., Moriuchi S.et al. Efficient gene delivery into Epstein-Barr virus (EBV)-transformed human B cell mediated by replication defective herpes simplex virus-1 (HSV-1): a gene therapy model for EBV-related B-cell malignancy. Biochem. Biophys. Res. Commun. 252:1998;686.
6. Boyum A. Separation of white blood cells. Nature. 204:1964;793.
7. Krisky DM, Marconi PC, Oligino T, Rouse RJ, Fink DJ, Glorioso JC. Rapid method for construction of recombinant HSV gene transfer vectors. Gene Ther 1997;1120.
8. Marconi P., Krisky D., Oligino T., Poliani P.L., Ramakrishman R., Goins W.F.et al. Replication-defective herpes simplex virus vectors for gene therapy. Proc. Natl. Acad. Sci. U.S.A. 93:1996;11319.
9. Glorioso J.C., Goins W.F., Schmidt M.C., Oligino T., Krisky D.M., Marconi P.C.et al. Engineering herpes simplex vectors for human gene therapy. Adv. Pharmacol. 40:1997;103.
10. Burton E.A., Glorioso J.C. Multi-model combination gene therapy for malignant glioma using replication-defective HSV vectors. Drug Discov. Today. 6:2001;347.
11. Rainov N.G. A phase III clinical evaluation of herpes simplex virus type-1 thymidine kinase and ganciclovir gene therapy as an adjuvant to surgical resection and radiation in adults with previously untreated glioblastoma multiforme. Hum. Gene Ther. 11:2000;2389.
12. Moriuchi S., Krisky D.M., Marconi P.C., Tamura M., Shimizu K., Yoshimine T.et al. HSV vector cytotoxicity is inversely correlated with effective TK/GCV suicide gene therapy of rat gliosarcoma. Gene Ther. 7:2000;1483.
13. Oyama M., Ohigashi T., Hoshi M., Murai M., Uyemura K., Yazaki T. Treatment of human renal cell carcinoma by a conditionally replicating herpes vector G207. J. Urol. 165:2001;1274.
14. Oyama M., Ohigashi T., Hoshi M., Murai M., Uyemura K., Yazaki T. Oncolytic viral therapy for human prostate cancer by conditionally replicating herpes simplex virus-1 vector G207. Jpn. J. Cancer Res. 91:2000;1339.
15. Lambright E.S., Caparrelli D.J., Abbas A.E., Toyoizumi T., Coukos G., Molnar-Kimber K.L.et al. Oncolytic therapy using a mutant type-1 herpes simplex virus and the role of the immune system. Ann. Thorac. Surg. 68:1999;1756.
16. Wang M., Rancourt C., Navarro J.G., Krisky D., Marconi P., Oligino T.et al. High-efficacy thymidine kinase gene transfer to ovarian cancer cell lines mediated by herpes simplex virus type-1 vector. Genecol. Oncol. 71:1998;278.
17. Yamamura H., Hashio M., Noguchi M., Sugenoya Y., Osakada M., Hirano N.et al. Identification of the transcriptional regulatory sequences of human calponin promoter and their use in targeting a conditionally replicating herpes vector to malignant human soft tissue and bone tumors. Cancer Res. 61:2001;3969.
18. Todo T., Martuza R.L., Rabkin S.D., Johnson P.A. Oncocytic herpes simplex vector with enhanced MHC class I presentation and tumor cell killing. Proc. Natl. Acad. Sci. U.S.A. 98:2001;6396.
19. Randazzo B.P., Kesari S., Gesser R.M., Alsop D., Ford J.C., Brown S.M.et al. Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus-1 mutant. Virology. 21:1995;94.
20. Yoon S.S., Carroll N.M., Chiocca E.A., Tanabe K.K. Influence of p53 on herpes simplex virus type-1 vectors for cancer gene therapy. J. Gastrointest. Surg. 3:1999;34.
21. Carroll N.M., Chiocca E.A., Takahashi K., Tanabe K.K. Enhancement of gene therapy specificity for diffuse colon carcinoma liver metastases with recombinant herpes simplex virus. Ann. Surg. 224:1996;323.
22. Fink D.J., Poliani P.L., Oligino T., Krisky D.M., Goin W.F., Glorioso J.C. Development of an HSV-based vector for the treatment of Parkinson's disease. Exp. Neurol. 144:1997;103.
23. Evans C., Goins W.F., Scmidt M.C., Robbins P.D., Ghivizzani S.C., Oligino T.et al. Progress in development of herpes simplex virus gene transfer for the treatment of rheumatoid arthritis. Adv. Drug. Deliv. Rev. 27:1997;41.
24. Tolba K.A., Bowers W.J., Hilchey S.P., Halterman M.W., Howard D.F., Giuliano R.E.et al. Development of herpes simplex virus-1 amplicon-based immunotherapy for chronic lymphocytic leukemia. Blood. 98:2001;287.
25. Hacein-Bey-Abina S., Le Deist F., Carlier F., Bouneaud C., Hue C., De Villartay J.P.et al. Sustained correction of X-linked severe immunodeficiency by ex vivo gene therapy. N. Engl. J. med. 346:2002;1185.
26. Marshall E. Clinical research. Gene therapy a suspect in leukemia-like disease. Science. 298:2002;34.
27. Diloo D., Rill D., Entwistle C., Boursnell M., Zhong W., Holden W.et al. A novel herpes vector for the high-efficiency transduction of normal and malignant hematopoietic cells. Blood. 89:1997;119.
28. Wechuck J., Wolfe D., Goins W., Glorioso J.C. Gene transfer to stem cells using herpes simplex virus type-1 (HSV-1) vectors. Mol. Ther. Suppl. 1:2001;47.
29. Eling D.J., Johnson P.A., Sharma S., Tufaro F., Kipps T.J. Chronic lymphocytic leukemia B cell are highly sensitive to infection by herpes simplex virus-1 via herpes virus-entry-mediator A. Gene Ther. 7:2000;1210.
30. Geraghty R.J., Krummenacher C., Cohen G.H., Eisenberg R.J., Spesr P.G. Entry of alpha-herpes viruses mediated by poliovirus receptor-related protein-1 and poliovirus receptor. Science. 280:1998;1618.
31. Warner M.S., Geraghty R.J., Martinez W.M., Montgomery R.I., Whitbeck J.C., Xu R.et al. A cell surface protein with herpes virus entry activity (HveB) confers susceptibility to infection by mutants of herpes simplex virus type-1, herpes simplex virus type-2, and pseudorabies virus. Virology. 246:1998;179.
32. Culver K.W., Ram Z., Wallbridge S., Ishii H., Oldfield E.H., Blaese R.M. In vitro gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science. 256:1992;1550.